264 related articles for article (PubMed ID: 27488471)
1. Diminished IL-17A levels may protect filarial-infected individuals from development of rheumatoid arthritis and systemic lupus erythematosus.
Panda AK; Das BK
Lupus; 2017 Apr; 26(4):348-354. PubMed ID: 27488471
[TBL] [Abstract][Full Text] [Related]
2. IL-17A haplotype confers susceptibility to systemic lupus erythematosus but not to rheumatoid arthritis in Mexican patients.
Montúfar-Robles I; Barbosa-Cobos RE; Alemán-Ávila I; Ramírez-Bello J
Int J Rheum Dis; 2019 Mar; 22(3):473-479. PubMed ID: 30398030
[TBL] [Abstract][Full Text] [Related]
3. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity.
Talaat RM; Mohamed SF; Bassyouni IH; Raouf AA
Cytokine; 2015 Apr; 72(2):146-53. PubMed ID: 25647269
[TBL] [Abstract][Full Text] [Related]
4. Absence of IL-17A in Litomosoides sigmodontis-infected mice influences worm development and drives elevated filarial-specific IFN-γ.
Ritter M; Krupp V; Wiszniewsky K; Wiszniewsky A; Katawa G; Tamadaho RSE; Hoerauf A; Layland LE
Parasitol Res; 2018 Aug; 117(8):2665-2675. PubMed ID: 29931394
[TBL] [Abstract][Full Text] [Related]
5. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
Gabay C; Cakir N; Moral F; Roux-Lombard P; Meyer O; Dayer JM; Vischer T; Yazici H; Guerne PA
J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
[TBL] [Abstract][Full Text] [Related]
6. IL-17 in cutaneous lupus erythematosus.
Tanasescu C; Balanescu E; Balanescu P; Olteanu R; Badea C; Grancea C; Vagu C; Bleotu C; Ardeleanu C; Georgescu A
Eur J Intern Med; 2010 Jun; 21(3):202-7. PubMed ID: 20493423
[TBL] [Abstract][Full Text] [Related]
7. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients.
Higgs BW; Zhu W; Richman L; Fiorentino DF; Greenberg SA; Jallal B; Yao Y
Int J Rheum Dis; 2012 Feb; 15(1):25-35. PubMed ID: 22324944
[TBL] [Abstract][Full Text] [Related]
8. Increased CCR4 expression on circulating CD4(+) T cells in ankylosing spondylitis, rheumatoid arthritis and systemic lupus erythematosus.
Yang PT; Kasai H; Zhao LJ; Xiao WG; Tanabe F; Ito M
Clin Exp Immunol; 2004 Nov; 138(2):342-7. PubMed ID: 15498047
[TBL] [Abstract][Full Text] [Related]
9. Different monocyte reaction patterns in newly diagnosed, untreated rheumatoid arthritis and lupus patients probably confer disparate C-reactive protein levels.
Liou LB
Clin Exp Rheumatol; 2003; 21(4):437-44. PubMed ID: 12942694
[TBL] [Abstract][Full Text] [Related]
10. Arthritis in systemic lupus erythematosus is characterized by local IL-17A and IL-6 expression in synovial fluid.
Sippl N; Faustini F; Rönnelid J; Turcinov S; Chemin K; Gunnarsson I; Malmström V
Clin Exp Immunol; 2021 Jul; 205(1):44-52. PubMed ID: 33576004
[TBL] [Abstract][Full Text] [Related]
11. Type I interferon and T helper 17 cells co-exist and co-regulate disease pathogenesis in lupus patients.
Biswas PS; Aggarwal R; Levesque MC; Maers K; Ramani K
Int J Rheum Dis; 2015 Jul; 18(6):646-53. PubMed ID: 25960196
[TBL] [Abstract][Full Text] [Related]
12. Impaired urinary excretion of soluble IL-2 receptors in patients with systemic lupus erythematosus and rheumatoid arthritis.
Manoussakis MN; Germanidis GS; Drosos AA; Moutsopoulos HM
Lupus; 1992 Feb; 1(2):105-9. PubMed ID: 1301961
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies to tumor necrosis factor in patients with rheumatoid arthritis and systemic lupus erythematosus.
Rosenau BJ; Schur PH
J Rheumatol; 2009 Apr; 36(4):753-6. PubMed ID: 19273453
[TBL] [Abstract][Full Text] [Related]
14. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity.
Houssiau FA; Lefebvre C; Vanden Berghe M; Lambert M; Devogelaer JP; Renauld JC
Lupus; 1995 Oct; 4(5):393-5. PubMed ID: 8563734
[TBL] [Abstract][Full Text] [Related]
15. Elevated plasma midkine and pleiotrophin levels in patients with systemic lupus erythematosus.
Wu GC; Yuan H; Pan HF; Ye DQ
Oncotarget; 2017 Jun; 8(25):40181-40189. PubMed ID: 27903979
[TBL] [Abstract][Full Text] [Related]
16. Serum interleukin-2 receptor in systemic lupus erythematosus and rheumatoid arthritis.
Lee GL; Chen MY; Chuang CY; Chen CY
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1988 Feb; 21(1):16-22. PubMed ID: 3264781
[TBL] [Abstract][Full Text] [Related]
17. IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE).
Oke V; Brauner S; Larsson A; Gustafsson J; Zickert A; Gunnarsson I; Svenungsson E
Arthritis Res Ther; 2017 Jun; 19(1):139. PubMed ID: 28619037
[TBL] [Abstract][Full Text] [Related]
18. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time.
Becker-Merok A; Nikolaisen C; Nossent HC
Lupus; 2006; 15(9):570-6. PubMed ID: 17080911
[TBL] [Abstract][Full Text] [Related]
19. A murine autoimmune model of rheumatoid arthritis and systemic lupus erythematosus associated with deregulated production of IL-17 and IL-21.
Biswas PS; Kang K; Gupta S; Bhagat G; Pernis AB
Methods Mol Biol; 2012; 900():233-51. PubMed ID: 22933072
[TBL] [Abstract][Full Text] [Related]
20. Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity.
Robak E; Sysa-Jedrzejewska A; Dziankowska B; Torzecka D; Chojnowski K; Robak T
Arch Immunol Ther Exp (Warsz); 1998; 46(6):375-80. PubMed ID: 9883317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
